Cheaper drugs and techniques to fulfill chief executive officer perspectives - any choices?

Betty E. Thomas, Thomas Ledowski

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: Against the background of increasing healthcare costs and diminishing budgets, this review aims to present clinicians with ethically viable options to overcome budgetary restraints when seeking to introduce novel products. RECENT FINDINGS: Healthcare administrators and primary healthcare providers are not unlikely to have different opinions when discussing the introduction of novel products. However, rather than taking a 'no' for an answer, doctors may be able to argue for a change - even if this may seem to come at a higher cost. The recent introduction of the reversal agent sugammadex may provide a timely example for the possibility of success 'against all financial odds'. SUMMARY: Health professionals have the responsibility to deliver high-quality care while acknowledging the financial budget constraints. However, evidence (vs. perception) for outcome benefits of novel drugs or devices should stimulate a robust desire for their timely introduction. Demonstrating actual benefits understandable to administrators, seeking alliances with other medical specialties or patient groups, as well as negotiations with the healthcare industry may all represent viable options. Simply waiting for patents to expire should remain a measure of last resort.

Original languageEnglish
Pages (from-to)195-199
Number of pages5
JournalCurrent Opinion in Anaesthesiology
Volume32
Issue number2
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint

Budgets
Administrative Personnel
Health Care Sector
Patents
Quality of Health Care
Negotiating
Pharmaceutical Preparations
Health Personnel
Health Care Costs
Primary Health Care
Medicine
Delivery of Health Care
Costs and Cost Analysis
Equipment and Supplies
Health
Sugammadex

Cite this

@article{9d37b2ce1464458c912cac15f9a27374,
title = "Cheaper drugs and techniques to fulfill chief executive officer perspectives - any choices?",
abstract = "PURPOSE OF REVIEW: Against the background of increasing healthcare costs and diminishing budgets, this review aims to present clinicians with ethically viable options to overcome budgetary restraints when seeking to introduce novel products. RECENT FINDINGS: Healthcare administrators and primary healthcare providers are not unlikely to have different opinions when discussing the introduction of novel products. However, rather than taking a 'no' for an answer, doctors may be able to argue for a change - even if this may seem to come at a higher cost. The recent introduction of the reversal agent sugammadex may provide a timely example for the possibility of success 'against all financial odds'. SUMMARY: Health professionals have the responsibility to deliver high-quality care while acknowledging the financial budget constraints. However, evidence (vs. perception) for outcome benefits of novel drugs or devices should stimulate a robust desire for their timely introduction. Demonstrating actual benefits understandable to administrators, seeking alliances with other medical specialties or patient groups, as well as negotiations with the healthcare industry may all represent viable options. Simply waiting for patents to expire should remain a measure of last resort.",
author = "Thomas, {Betty E.} and Thomas Ledowski",
year = "2019",
month = "4",
day = "1",
doi = "10.1097/ACO.0000000000000689",
language = "English",
volume = "32",
pages = "195--199",
journal = "Current Opinion in Anaesthesiology",
issn = "0952-7907",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

Cheaper drugs and techniques to fulfill chief executive officer perspectives - any choices? / Thomas, Betty E.; Ledowski, Thomas.

In: Current Opinion in Anaesthesiology, Vol. 32, No. 2, 01.04.2019, p. 195-199.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cheaper drugs and techniques to fulfill chief executive officer perspectives - any choices?

AU - Thomas, Betty E.

AU - Ledowski, Thomas

PY - 2019/4/1

Y1 - 2019/4/1

N2 - PURPOSE OF REVIEW: Against the background of increasing healthcare costs and diminishing budgets, this review aims to present clinicians with ethically viable options to overcome budgetary restraints when seeking to introduce novel products. RECENT FINDINGS: Healthcare administrators and primary healthcare providers are not unlikely to have different opinions when discussing the introduction of novel products. However, rather than taking a 'no' for an answer, doctors may be able to argue for a change - even if this may seem to come at a higher cost. The recent introduction of the reversal agent sugammadex may provide a timely example for the possibility of success 'against all financial odds'. SUMMARY: Health professionals have the responsibility to deliver high-quality care while acknowledging the financial budget constraints. However, evidence (vs. perception) for outcome benefits of novel drugs or devices should stimulate a robust desire for their timely introduction. Demonstrating actual benefits understandable to administrators, seeking alliances with other medical specialties or patient groups, as well as negotiations with the healthcare industry may all represent viable options. Simply waiting for patents to expire should remain a measure of last resort.

AB - PURPOSE OF REVIEW: Against the background of increasing healthcare costs and diminishing budgets, this review aims to present clinicians with ethically viable options to overcome budgetary restraints when seeking to introduce novel products. RECENT FINDINGS: Healthcare administrators and primary healthcare providers are not unlikely to have different opinions when discussing the introduction of novel products. However, rather than taking a 'no' for an answer, doctors may be able to argue for a change - even if this may seem to come at a higher cost. The recent introduction of the reversal agent sugammadex may provide a timely example for the possibility of success 'against all financial odds'. SUMMARY: Health professionals have the responsibility to deliver high-quality care while acknowledging the financial budget constraints. However, evidence (vs. perception) for outcome benefits of novel drugs or devices should stimulate a robust desire for their timely introduction. Demonstrating actual benefits understandable to administrators, seeking alliances with other medical specialties or patient groups, as well as negotiations with the healthcare industry may all represent viable options. Simply waiting for patents to expire should remain a measure of last resort.

UR - http://www.scopus.com/inward/record.url?scp=85062405586&partnerID=8YFLogxK

U2 - 10.1097/ACO.0000000000000689

DO - 10.1097/ACO.0000000000000689

M3 - Article

VL - 32

SP - 195

EP - 199

JO - Current Opinion in Anaesthesiology

JF - Current Opinion in Anaesthesiology

SN - 0952-7907

IS - 2

ER -